To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. VWR will not lift restrictions for residential shipping addresses.
Spécifications
- Description:ERK Phosphorylation Assay Kit
- Size:100 assays
- Method:FL360/450 nm, 530/585 nm
- Sample:Cells
- Processing time:Eight hours
- Cat. no.:75878-108
- Supplier No.:EERK-100
- Species Reactivity:Human, mouse, rat
Spécifications
A propos de cet article
For quantitative fluorescent immunoenzymatic assay of ERK1/2 phosphorylation status in cultured cells.
- Safe
- Non-radioactive assay
- Total and pERK can be measured in the same sample
The mitogen-activated protein kinase (MAPK/ERK) pathway plays a key role in cell proliferation, differentiation and migration
BioAssay Systems’ cell-based ELISA measures dually phosphorylated ERK1/2 in whole cells and normalizes the signal to the total protein content. This simple and efficient assay eliminates the need for cell lysate preparation and can be used to study kinase signaling and the effects of kinase inhibitors on cells. In this assay, cells are grown in 96-well plates and treated with ligands or drugs. Cells are then fixed and permeabilized in the wells. ERK1/2 phosphorylation (pERK) using a fluorescent ELISA followed by total protein measurement in each well.
Stimulation by mitogens eventually leads to phosphorylation of ERK1 (T202/Y204) and ERK2 (T185/Y187). The MAPK/ERK cascade presents many interesting drug targets for the development of cancer therapies.